New Three-Drug attack on tough lymphomas
NCT ID NCT05025800
Summary
This study is testing a new three-drug combination to control B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see if adding a new immunotherapy drug (ALX148) to two existing drugs (rituximab and lenalidomide) helps patients whose cancer has returned or is newly diagnosed with high tumor burden. The trial is for adults with specific types of B-cell lymphoma who meet strict health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.